Streetbeat News

Products Services

KPRX

Kiora Pharmaceuticals has announced positive topline results from its Phase 1/2 trial, demonstrating that KIO-301 has the potential to significantly improve vision in patients with retinitis pigmentosa who have ultra-low vision or complete blindness.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:18 am

MNKD

MannKind Corporation (NASDAQ:MNKD) has completed enrollment for its INHALE-3, a Phase 4 clinical trial. The trial is evaluating inhaled insulin (combined with basal insulin) versus usual care in adults living with type 1 diabetes.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:17 am

JD

JD Worldwide, the international business arm of JD.com, plans to roll out enhanced authentication processes for imported goods, named 'JD Smart Check'.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:16 am

AMZN

MDB

MongoDB (MDB) and Amazon Web Services (AWS) have collaborated to optimize Amazon CodeWhisperer, a tool that provides suggestions to developers. This partnership aims to enhance the efficiency and productivity of developers using the platform.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:03 am

TM

TSLA

Toyota Motor Corp (NYSE:TM) is reportedly striving to match the production pace of Tesla Inc (NASDAQ:TSLA) in the EV market. Toyota is making progress in solid-state battery technology and investing in the US EV market, but is challenged by Tesla's gigacasting assembly process. Toyota has stated it will not fully embrace Tesla’s gigacasting technique, instead leveraging its expertise to carve out its unique path.

Portfolio Pulse from Anan Ashraf

November 06, 2023 | 11:00 am

AAPL

Apple Inc. reported Q4 results that exceeded estimates but faced questions about future growth. The company's sales are expected to be flat or possibly decline again, with no new iPad released this year and minor updates to other products. Apple has increased prices for services like Apple TV+, Arcade, and News+, but this may not be enough to boost revenues. The company's ambitious projects, Apple Car and Vision Pro, are still in development, with the latter expected to launch in 2024. However, the high price tag of $3,500 may limit its appeal.

Portfolio Pulse from Ananya Gairola

November 06, 2023 | 10:37 am

KOD

Kodiak Sciences has announced that its Phase 3 GLOW Superiority Study of Tarcocimab Tedromer 5 mg in moderately severe to severe non-proliferative diabetic retinopathy has met its one-year primary endpoint.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 10:08 am

CRSP

Crispr Therapeutics has announced preclinical data from its investigational programs for the treatment of cardiovascular disease. The data shows that CTX310 and CTX320 led to durable reductions of ANGPTL3 protein and lipoprotein(a) levels respectively in non-human primates after a single dose. Both were well-tolerated at clinically relevant dose levels. A clinical trial has been initiated for CTX310, while CTX320 is set to enter the clinic in the first half of 2024.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 10:05 am

PSNY

Swedish electric vehicle manufacturer Polestar (NASDAQ:PSNY) has partnered with South Korea's leading battery producer, SK On, for the supply of battery cell modules for its upcoming Polestar 5 electric 4-door GT. The decision was influenced by SK On's advanced battery cell technology, which is known for its high-performing chemistry, quick charging, and efficient discharging capabilities. The Polestar 5 is expected to begin production in 2025.

Portfolio Pulse from Benzinga Neuro

November 06, 2023 | 9:41 am

IMMP

Immutep Limited has announced the completion of the safety lead-in and the opening of the randomized Phase II of the AIPAC-003 Phase II/III trial in metastatic breast cancer. The trial is evaluating the combination of 90mg of eftilagimod alpha (efti) with paclitaxel, with no safety or tolerability issues reported.

Portfolio Pulse from Charles Gross

November 06, 2023 | 9:41 am